Ajanta Pharma has received USFDA approval for launch of Amlodipine + Olmesartan Medoxomil Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent generic version of Azor tablets, used for lowering blood pressure and company has launched the product in 4 strengths, 5mg+20mg, 5mg+40mg, 10mg+20mg, 10mg+40mg tablets.
Amlodipine + Olmesartan Medoxomil Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Application (ANDA) of which it has for 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with USFDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. The company is engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: